Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Rating of "Buy" by Analysts
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Rating of "Buy" by Analysts
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Rating) has received a consensus rating of "Buy" from the six research firms that are currently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $51.60.
据MarketBeat报道,Arcutis BioTreateutics,Inc.(纳斯达克代码:ARQT-GET评级)已收到目前覆盖该股的六家研究公司的共识评级为买入。六位股票研究分析师已将该股评级为买入建议。在去年发布了一份股票报告的分析师中,平均一年的价格目标是51.60美元。
Separately, Morgan Stanley lifted their price objective on Arcutis Biotherapeutics from $49.00 to $51.00 and gave the stock an "overweight" rating in a report on Tuesday, December 13th.
另外,摩根士丹利在12月13日(星期二)的一份报告中将Arcutis BioTreateutics的目标价从49.00美元上调至51.00美元,并给予该股“增持”评级。
Insiders Place Their Bets
内部人士下注
In other news, Director Howard G. Welgus sold 8,500 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $13.72, for a total value of $116,620.00. Following the completion of the transaction, the director now owns 165,825 shares in the company, valued at approximately $2,275,119. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, insider Masaru Matsuda sold 1,720 shares of the business's stock in a transaction that occurred on Monday, November 21st. The stock was sold at an average price of $18.19, for a total transaction of $31,286.80. Following the completion of the transaction, the insider now owns 19,535 shares in the company, valued at approximately $355,341.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Howard G. Welgus sold 8,500 shares of the business's stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $13.72, for a total value of $116,620.00. Following the transaction, the director now owns 165,825 shares of the company's stock, valued at approximately $2,275,119. The disclosure for this sale can be found here. Insiders have sold 13,695 shares of company stock worth $205,107 in the last three months. 23.00% of the stock is owned by insiders.
在其他新闻方面,董事霍华德·G·韦尔格斯在1月17日(星期二)的一笔交易中出售了8,500股Arcutis BioTreateutics的股票。这只股票的平均售价为13.72美元,总价值为116,620.00美元。交易完成后,董事现在拥有该公司165,825股票,价值约2,275,119美元。这笔交易是在提交给美国证券交易委员会的法律文件中披露的,该文件可通过此超链接。在相关新闻中,内部人士松田正郎在11月21日星期一的一次交易中出售了1,720股该公司的股票。该股以18.19美元的平均价格出售,总成交金额为31286.80美元。交易完成后,这位内部人士现在拥有该公司19,535股,价值约355,341.65美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可在美国证券交易委员会网站。此外,董事霍华德·G·韦尔格斯在1月17日(星期二)的一笔交易中出售了8,500股该公司的股票。这些股票的平均价格为13.72美元,总价值为116,620.00美元。交易完成后,董事现在拥有该公司165,825股股票,价值约2275,119美元。关于这次销售的披露可以找到这里。在过去的三个月里,内部人士已经出售了13,695股公司股票,价值205,107美元。23.00%的股份由内部人士持有。
Institutional Inflows and Outflows
机构资金流入和流出
Arcutis Biotherapeutics Stock Performance
Arcutis BioTreateutics股票表现
Shares of NASDAQ:ARQT opened at $16.67 on Friday. The company has a market cap of $1.02 billion, a P/E ratio of -2.83 and a beta of 0.52. The company has a debt-to-equity ratio of 0.73, a quick ratio of 13.27 and a current ratio of 13.39. Arcutis Biotherapeutics has a one year low of $12.81 and a one year high of $27.40. The business's 50-day simple moving average is $15.62 and its 200 day simple moving average is $18.92.
纳斯达克:ARQT周五开盘报16.67美元。该公司市值为10.2亿美元,市盈率为-2.83,贝塔系数为0.52。该公司的负债权益比率为0.73,速动比率为13.27,流动比率为13.39。Arcutis BioTreateutics的一年低点为12.81美元,一年高位为27.40美元。该业务的50日简单移动均线切入位为15.62美元,200日简单移动均线切入位为18.92美元。
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Rating) last announced its earnings results on Tuesday, November 8th. The company reported ($1.89) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.35). The company had revenue of $0.73 million during the quarter, compared to analyst estimates of $1.01 million. On average, sell-side analysts forecast that Arcutis Biotherapeutics will post -5.96 earnings per share for the current fiscal year.
Arcutis BioTreateutics(纳斯达克:ARQT-GET评级)最近一次公布收益业绩是在11月8日(星期二)。该公司公布本季度每股收益(1.89美元),低于普遍预期的(1.54美元)和(0.35美元)。该公司本季度营收为73万美元,而分析师预期为101万美元。卖方分析师平均预测,Arcutis BioTreateutics本财年每股收益将达到5.96美元。
About Arcutis Biotherapeutics
关于Arcutis生物疗法
(Get Rating)
(获取评级)
Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
Arcutis BioTreateutics,Inc.是一家生物制药公司,专注于皮肤病治疗方法的开发和商业化。它的主要候选产品是ARQ-151,这是一种外用罗氟司特乳膏,已经完成了治疗斑块型牛皮癣和特应性皮炎的第三阶段临床试验。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Arcutis Biotherapeutics (ARQT)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- 免费获取StockNews.com关于弓状生物疗法(ARQT)的研究报告
- 市场回顾周-1/30-2/3
- 细价股值得吗?你应该投资细价股吗?
- Zimmer Biomet盈利节节攀升,增长可能被计入价格
- 人工智能软件制造商EPAM号称科技板块涨幅最大
- 福特股票在盈利大幅下滑后继续前进
Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Arcutis BioTreatetics Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Arcutis BioTreateutics和相关公司的最新新闻和分析师评级的每日简要摘要。